EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor

Lauren Linenfelser iD, Melissa Lipari iD, Pramodini Kale-Pradhan iD

Annals of Pharmacotherapy · 06.08.2026

DOI: 10.1177/10600280261472893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 06.08.2026. Verfasst von Lauren Linenfelser und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the pharmacology, efficacy, and safety of subcutaneous depemokimab-ulaa as add-on therapy in the treatment of severe eosinophilic asthma. Data Sources: PubMed database, Embase, and ClinicalTrials.gov were searched using the following terms: depemokimab, depemokimab-ulaa, Exdensur, and GSK3511294. Study Selection and Data Extraction: Articles published in English between January 2020 and March 2026, related to pharmacology, safety, efficacy, and clinical trials, were reviewed. Four studies met inclusion criteria. Data Synthesis: In phase 3 trials, SWIFT-1 and SWIFT-2, depemokimab-ulaa demonstrated comparable reductions in elevated blood eosinophil (EOS) counts when compared to other interleukin-5 (IL-5) targeting therapies in patients with severe eosinophilic asthma. The annualized exacerbation rates were 0.46 and 0.56 with depemokimab-ulaa vs 1.11 and 1.08 with placebo ( P < .001), respectively. There were no differences in other outcomes that were studied. In the phase 3 NIMBLE trial, depemokimab-ulaa did not meet the noninferiority margin when patients were switched from other anti-IL-5 therapies. Depemokimab-ulaa maintained a favorable safety profile, with no serious adverse events or deaths considered to be related to the drug. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: When compared with other anti-IL-5 agents, depemokimab-ulaa might serve as an effective alternative option with its twice-yearly dosing offering a significant advantage potentially improving patient adherence and clinical outcomes.

Conclusion

Depemokimab-ulaa’s twice-yearly dosing offers a convenient alternative to other anti-IL-5 therapies as add-on treatment for severe eosinophilic asthma.

Schlagwörter

Stichwörter der Autor:innen

ExdensurGSK3511294depemokimabdepemokimab-ulaa

Autor:innen und Institutionen

  • Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
  • Henry Ford St. John Hospital, Wayne State University, Detroit, MI, USA.

ORCID-Profile: Lauren Linenfelser, Melissa Lipari, Pramodini Kale-Pradhan

Zitieren

APA

Linenfelser, L., Lipari, M., & Kale-Pradhan, P. (2026). Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261472893

Vancouver

Linenfelser L, Lipari M, Kale-Pradhan P. Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261472893

BibTeX
@article{Linenfelser2026,
  author = {Linenfelser, Lauren and Lipari, Melissa and Kale-Pradhan, Pramodini},
  title = {Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261472893}
}
Kostenlos starten →